SCHEMBL6185142

SCHEMBL6185142

CCN1CCC(C)CC1.[CH2]CCN1CCN(C)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
PRMT1 Q99873 1/20 0.43
PRMT8 Q9NR22 1/20 0.43
HRH3 Q9Y5N1 5/20 0.38
ACHE P22303 2/20 0.38
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37
SIGMAR1 Q99720 5/20 0.36
GNAI3 P08754 1/20 0.35
GNAO1 P09471 1/20 0.35
GNAI1 P63096 1/20 0.35
KDM4E B2RXH2 1/20 0.35
RECQL P46063 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MAOB P27338 1/20 0.35
HRH2 P25021 1/20 0.35
HRH1 P35367 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183476 0.95 CARM1 (0.40) CARM1PRMT6PRMT1PRMT8HRH3
SCHEMBL27327213 0.87 CARM1 (0.45) CARM1PRMT6PRMT1PRMT8HRH3
SCHEMBL6185138 0.86 GNAI3 (0.39) HRH3GNAI3GNAO1GNAI1SMN1; SMN2
SCHEMBL1196444 0.84 CARM1 (0.56) CARM1PRMT6PRMT1PRMT8HRH3
SCHEMBL18823228 0.82 CARM1 (0.54) CARM1PRMT6PRMT1PRMT8HRH3
SCHEMBL19853579 0.80 CARM1 (0.56) CARM1PRMT6PRMT1PRMT8HRH3
SCHEMBL293752 0.80 MAPK1 (0.38) SIGMAR1KDM4ESMN1; SMN2
SCHEMBL6183469 0.80 GNAI3 (0.40) GNAI3GNAO1GNAI1SMN1; SMN2
SCHEMBL230142 0.78 PAOX (0.40) HRH3SIGMAR1
SCHEMBL81186 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1499594-B1 PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES WYETH CORP (US) 2005-08-17 EP disclosed
EP-1499594-A1 PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES Wyeth Holdings Corporation (US) 2005-01-26 EP disclosed
US-6780996-B2 KINASE INHIBITORS; ANTICANCER AGENTS WYETH HOLDINGS CORPORATION 2004-08-24 US disclosed
US-20030212276-A1 Process for the preparation of 7-substituted-3 quinolinecarbonitriles WYETH HOLDINGS CORPORATION 2003-11-13 US disclosed
WO-2003093241-A1 PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES WYETH HOLDINGS CORPORATION (US) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212276-A1 Process for the preparation of 7-substituted-3 quinolinecarbonitriles MAP4K2, MAP3K7, MAP4K1 CARM1 3168/4885PRMT6 1457/4885PRMT1 1375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.